Program
AZD0292
A development code.
Its studies are mostly in Bronchiectasis, led by AstraZeneca.
Furthest: phase 2, since Jul 17, 20254 company-led studies, 2 open or runningNext primary completion: Dec 9, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 42 open or running | phase 2since Jul 17, 2025 | Mar 8, 2024 | Dec 9, 2027phase 2 · NCT07088926 |
- Named in AstraZeneca’s own pipeline as
AZD0292
, phase 2, as of Oct 30, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 8, 2024First study: phase 1 study in Healthy Participants StudyFirst studyNCT06311760 · 32 enrolled · United States
- Jul 17, 2025Phase 2 study in Bronchiectasis With Pseudomonas Aeruginosa ColonizationNCT07088926 · 435 planned · United States, Argentina, Australia and more
- Oct 28, 2025Phase 1 study in Healthy ParticipantsNCT07222254 · 18 enrolled · Japan
- Jun 24, 2026Phase 2 study in Bronchiectasis With Pseudomonas Aeruginosa ColonizationNCT07774403 · 84 planned · China
Ahead
- Dec 9, 2027Primary completion: phase 2 study in Bronchiectasis With Pseudomonas Aeruginosa ColonizationNCT07088926
- Jan 18, 2028Primary completion: phase 2 study in Bronchiectasis With Pseudomonas Aeruginosa ColonizationNCT07774403
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“AZD0292 is a bispecific IgG1k mAb being evaluated for the prevention of exacerbations in bronchiectasis patients chronically colonized with PsA.”study summary, read by Claude · the study
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07774403Bronchiectasis With Pseudomonas Aeruginosa Colonization · China | 2 | Recruiting | Jan 18, 2028 | 84 |
| NCT07222254Healthy Participants · Japan | 1 | Completed | Jul 30, 2026 | 18 |
| NCT07088926Bronchiectasis With Pseudomonas Aeruginosa Colonization · United States, Argentina, Australia and more | 2 | Recruiting | Dec 9, 2027 | 435 |
| NCT06311760Healthy Participants Study · United States | 1 | Completed | Feb 20, 2025 | 32 |
How it is read
Names in the registry
- “AZD0292”, 4 entries
Codes read as this program: AZD0292.
Conditions, from the studies’ own filings
- Bronchiectasis, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.